ArticleJournal of clinical tuberculosis and other mycobacterial diseases2026
QT interval prolongation in patients receiving bedaquiline-based regimens for drug-resistant tuberculosis in Sub-Saharan Africa: A systematic review and meta-analysis.
Article in Journal of clinical tuberculosis and other mycobacterial diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Drug-resistant tuberculosis (DR-TB) is a major public health challenge in Sub-Saharan Africa (SSA), worsened by high HIV prevalence and limited healthcare infrastructure. Bedaquiline, a cornerstone DR-TB treatment, is linked to QT interval prolongation, a risk factor for life-threatening arrhythmias. This systematic review and Methods: Following PRISMA guidelines, we searched PubMed, Embase, Cochrane Library, Web of Science, and African Journals Online (2013-2024). Studies reporting QT intervals in DR-TB patients receiving bedaquiline in SSA were included (QTc > 450 ms men/>460 ms women). A random-effects model with Freeman-Tukey transformation estimated pooled incidence. Subgroup and sensitivity analyses explored heterogeneity (I Results: From 616 records, 23 studies (6673 bedaquiline-exposed patients) were included; 19 studies with 6158 patients contributed to the Conclusion: QT prolongation is significant in SSA's bedaquiline-treated DR-TB patients, necessitating enhanced ECG monitoring and integrated TB-HIV care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.